Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Prohaska

MOHS-Micrographic Surgery Morristown, TN Doctor of Osteopathy

NPI 1790158012 CMS profile 2780864

1907 W Morris Blvd Ste G, Morristown, TN 37813

Open in the dashboard

General payments

$10,934

537 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,934 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Joseph Prohaska of Morristown, TN is reported in the CMS Open Payments database as having received $10,934 across 537 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,934 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,923 86
2024 General $2,286 91
2023 General $1,614 80
2022 General $1,454 74
2021 General $1,634 98
2020 General $1,256 76
2019 General $766 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Prohaska
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Joseph Prohaska were reported at $1,923. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Joseph Prohaska MOHS-Micrographic Surgery median Middle half National median
2019 $766 $316 $106–$785 $163
2020 $1,256 $162 $68–$412 $114
2021 $1,634 $243 $87–$654 $132
2022 $1,454 $300 $102–$887 $149
2023 $1,614 $364 $125–$1,010 $160
2024 $2,286 $445 $142–$1,108 $164
2025 $1,923 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,533 154 payments
  2. Novartis Pharmaceuticals Corporation $1,517 67 payments
  3. Lilly USA, LLC $1,469 61 payments
  4. Janssen Biotech, Inc. $849 32 payments
  5. Sun Pharmaceutical Industries Inc. $788 34 payments
  6. UCB, Inc. $688 29 payments
  7. Amgen Inc. $529 27 payments
  8. LEO Pharma Inc. $412 35 payments
  9. Regeneron Healthcare Solutions, Inc. $365 17 payments
  10. Pfizer Inc. $186 11 payments
  11. Other $1,599 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,664 531 payments
  2. Education $270 6 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $1,636 105 payments
  2. HUMIRA $1,064 56 payments
  3. TALTZ $1,041 56 payments
  4. TREMFYA $698 23 payments
  5. COSENTYX Dermatology $584 24 payments
  6. COSENTYX Immunology $565 25 payments
  7. OLUMIANT $510 21 payments
  8. ILUMYA $495 27 payments
  9. Otezla $421 21 payments
  10. Bimzelx $397 15 payments
  11. Other $4,589 257 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,297

Median for Dermatology: 534

Drug cost

$110,506

Median for Dermatology: $67,151

Branded share of claims

1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 13 $92,817
Mupirocin Generic 689 $6,246
Clobetasol Propionate Generic 61 $3,314
Fluocinolone Acetonide Generic 37 $2,156
Ketoconazole Generic 104 $1,772
Fluorouracil Generic 17 $1,296
Triamcinolone Acetonide Generic 63 $896
Cephalexin Generic 175 $791
Doxycycline Hyclate Generic 80 $612
Ammonium Lactate Generic 18 $368

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$326,141

Of which drugs: $75,868

Medicare patients

434

Average age 75

Services billed

2,667

194 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 34%
Ischemic heart disease 27%
Chronic kidney disease 26%
COPD 25%
Depression 22%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Artacent ac, per square centimeter Q4190 Office 11 231 $58,001
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 34 62 $17,818

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
$323 — —
Bimzelx
$230 — —
COSENTYX
$219 — —
TREMFYA
$211 — —
Otezla
$136 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

537 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record